

Human anti-Alpha Hemolysin (Hla) mAb (327)

Catalog #: 0221-003

Description:

Human monoclonal antibody reactive to *Staphylococcus aureus* Alpha Hemolysin.

Immunogen/ Target:

Alpha Hemolysin (Hla)

Formulation & Storage: Supplied in PBS in frozen format with no preservatives added. **Store at +4°C** for 2-3 weeks; **-80°C** for long-term

Notes & Usage Guidelines:

Clonality/Isotype: Monoclonal; IgG1

Host: Human


ELISA: Assay-dependent dilution

WB: Assay-dependent dilution

Applications

Western Blot Data:

Western blot detection of Hla (lane 1), LukF (lane 2), LukS (lane 3), SEA (lane 4) and SEB (lane 5), 200ng each. Hla was detected with monoclonal antibody 327 at 0.50 µg/mL and an anti-human IgG-HRP conjugate.



ELISA Data:

S. aureus antigens were diluted to 2 µg/mL in PBS for plate coating. Anti-Hla antibody 327 was serially diluted ten-fold from 100 µg/mL and incubated on the coated plates. Washed plates were detected with anti-human IgG-HRP conjugate and TMB substrate. OD₆₅₀ is reported below.

ng/mL	OD 650 nm				
	Hla	LukF	LukS	SEA	SEB
100.000	3.708	0.26	0.334	0.074	0.085
10.000	3.722	0.081	0.066	0.065	0.172
1.000	3.706	0.085	0.082	0.098	0.073
0.100	3.564	0.098	0.078	0.077	0.074
0.010	3.071	0.064	0.073	0.070	0.083
0.001	1.057	0.092	0.071	0.063	0.071
0.000	0.226	0.103	0.072	0.067	0.073
0.000	0.104	0.070	0.090	0.073	0.201

Certificate of analysis:

A hardcopy of datasheet is sent along with the products. Please refer to it for detailed information. For older lots, refer to the applicable certificate of analysis that may be requested at products@ibtbioservices.com.

Related Products:

IBT provides a wide array of antibodies, recombinant proteins, and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, LLC.

Copyright 2023. Integrated BioTherapeutics, LLC. All rights reserved.